Physiomics PLC Contract award (7002H)

TIDMPYC

RNS Number : 7002H

Physiomics PLC

08 April 2022

8 April 2022

Physiomics plc

("Physiomics") or ("the Company")

Contract award

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded a contract by new client, the Servier Group ("Servier"), an international pharmaceutical company headquartered in France. Cancer is one of Servier's priority therapy areas and it has a particular focus on immunotherapies and monoclonal antibodies for difficult to treat diseases with high unmet medical needs.

Physiomics will be providing specialist mathematical modelling services using its Virtual Tumour software platform to model and simulate the effect of a number of immuno-oncology combinations involving Servier drugs in development in pre-clinical and clinical settings. It is anticipated that the project will be completed over the course of the next 7-8 months.

Physiomics CEO, Dr Jim Millen, commented : "We are delighted to have been selected by Servier, one of France's leading pharmaceutical companies with a truly global outlook as its partner for this modelling and simulation project focused on pre-clinical and translational modelling of a novel immuno-oncology agent in development. We look forward to working with its talented scientists."

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

[phone]

Hybridan LLP (broker)

Claire Louise Noyce

[phone]

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

[phone]

Notes to Editor

About Physiomics

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour(TM) technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 90 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

CNTUPUBUCUPPGAM

(END) Dow Jones Newswires

April 08, 2022 02:00 ET (06:00 GMT)